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Abstract
The rate of fungal infections is increasing rapidly, and pathogenesis of their
species is poorly understood. Among fungi, Candida species are a major cause of
morbidity and mortality worldwide and thus represent a serious threat to public
health. In addition, Cryptococcus spp. are yeasts responsible for serious lung infec-
tions and meningitis. Polyenes, fluoropyrimidines, echinocandins, and azoles are
used as commercial antifungal agents to treat fungal infections. However, the pres-
ence of intrinsic and developed resistance against azole antifungals has been exten-
sively documented. The re-emergence of classical fungal diseases has occurred
because of the increment of the antifungal resistance phenomenon. In this way, the
development of new satisfactory therapy for fungal diseases persists as a major
challenge of present-day medicine. The urgent need includes the development of
alternative drugs that are more efficient and tolerant than those traditional already
in use. The identification of new substances with potential antifungal effect at low
concentrations or in combination is also a possibility. This chapter briefly examines
the infections caused by Candida and Cryptococcus species and focuses on describing
some of the promising alternative molecules and/or substances that could be used as
antifungal agents, their mechanisms of action, and their use in combination with
traditional drugs.
Keywords: medicinal plants, yeast infections, antifungal agents,
antifungal activity, phytochemicals
1. Introduction
Fungal infections are considered a serious health problem, especially in people
with weakened immune systems, and are a main cause of morbidity and mortality
worldwide [1].
However, the impact of these “opportunistic” diseases on human health is not
widely highlighted [2]. Due to this, research related to fungi occurs slowly
compared to those caused by other pathogens.
Among the different mycotic infections, those caused by Candida and Crypto-
coccus are the most threatening due to severity of the disease and higher worldwide
occurrence [3]. The pathogenicity of fungal infections proceeds in well-organized
steps. For example, Candida cell surface adhesion factors first promote its
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adherence to host surface, followed by releasing of various hydrolytic enzymes and
other virulence factors for invasion and damage of the host tissues [4].
Candida species can cause a variety of infections from the mildest to the most
severe being candidemia the most frequent hospital infection accounting for up to
15% of bloodstream infections. Candida species are the main causative agents in
50–70% of systemic fungal infections [5].
Cryptococcus species are other yeasts of medical importance, with more than
39 species, among which Cryptococcus gattii and Cryptococcus neoformans are the
most clinically relevant [6–8]. However, other species such as Cryptococcus albidus
and Cryptococcus laurentii are emerging pathogens involved in several types of
infections [6, 9–11].
These yeasts are present in several environmental niches, such as woody sites
(decomposing tree trunks, mainly eucalyptus, and soil), vegetable remains, domes-
tic dust, and bird excrement, more precisely in Columba livia [12–14]. The source of
the infection is exogenous and occurs primarily by inhalation or by direct inocula-
tion into the tissue after trauma of desiccated spores or yeasts. It is believed that the
only source of infection is environmental, since there are no reports of transmission
between animals and humans or between humans [15].
The main virulence factors of Cryptococcus species are growth capacity at 37°C,
polysaccharide capsule, melanin synthesis, and production of urease and antioxi-
dant enzymes, causing primary or opportunistic cryptococcosis, such as pulmonary,
cutaneous, and meningitis diseases [6, 8, 13, 16–19]. Cryptococcosis is the third
opportunistic infection associated with AIDS [20].
In addition to delays in yeast diagnosis, there is currently a limited antifungal
armamentarium in use against yeast diseases including only four chemical classes:
polyenes, triazoles, echinocandins, and flucytosine. Antifungals act by binding spe-
cific components of fungal plasma membrane or its biosynthetic pathways or even
cell wall components [21]. However, most of the antifungal agents used in the clinic
is fungistatic and often led to the development of resistance by fungal species.
Modern early antifungal treatment strategies, such as prophylaxis and empirical and
preemptive therapy, result in long-term exposure to antifungal agents, which is a
major driving force for the development of resistance.
Among the available antifungal agents, azoles are the preferred and most fre-
quently used drugs for treatment of Candida and Cryptococcus infections. Flucona-
zole (FLZ), a type of azole, is often preferred in treatments of Candida infections
because of its low cost and toxicity, in addition to availability in varied formulations
[22]. However, there are many reports that described resistance development
among Candida species, especially in relation to azoles.
Infectious Diseases Society of America recommends the treatment of
cryptococcosis through FLZ and amphotericin B (AMB) with or without combina-
tion with 5-flucytosine (5-FC), followed by prolonged maintenance with flucona-
zole. Other azole compounds such as itraconazole (ITC), voriconazole, and
posaconazole may be used as an alternative to FLZ in cases of contraindication or
inefficacy of the latter [23, 24]. However, there has been a progressive increase in
isolates of Cryptococcus spp. resistant to FLZ, which complicates the management of
cryptococcal meningitis [25]. On the other hand, AMB and 5-FC are not available
in all countries and are, respectively, nephrotoxic and hepatotoxic, limiting the
anti-cryptococcal therapeutic [24].
Considering the limited availability of antifungals in use and the emergence of
resistance, the control of Candida and Cryptococcus infections is a challenge in the
modern clinic. In this way there is a continuous need for the search for new sub-
stances with new mechanisms of action with the aim of developing novel broad
spectrum antifungal drugs with better efficacy.
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In this way, plants stand out as the major producers of promising substances, the
phytochemicals. Identification of new molecules with antifungal potential for the
manufacture of new drugs, more effective and less toxic, is essential to facing the
challenge. The use of phytochemicals alone or in combination with traditional drugs
represents an important alternative to conventional therapy. The combination of
drugs usually requires lower doses of antimicrobials. This reduction might lead to a
toxicity decrease, which results in a higher tolerance to the antimicrobial by the
patient.
2. Pathogenic yeast infections: a serious health problem
In the last two decades, fungal infections have shown a significant increment. In
addition to the increase in the number of patients with compromised immune
system, factors such as increasing number of patients using catheters, the use of
broad-spectrum antibiotics, the rising number of patients requiring organ trans-
plantations, as well as those with hematological malignancies and diabetes also
contribute to this phenomenon [26, 27].
Even though fungal infections cause significant amount of human morbidity and
mortality, the impact of these “opportunistic” diseases on human health is not
widely highlighted [2]. Due to this, the research into the pathophysiology of human
fungal infections is slow in comparison to other disease-causing pathogens.
Recently, an editorial published in the journal Nature Microbiology [28] ratified the
importance of not neglecting fungi. The call proposed a reflection on fungi and how
these microorganisms have been neglected, even with studies already consolidated
showing their medical relevance.
The most frequent fungal diseases affecting populations in the world are candi-
diasis [29–34] and cryptococcosis [8, 20, 25]. There are several types of candidiasis
as mucosal candidiasis, cutaneous candidiasis, onychomycosis, systemic candidiasis
[35, 36], and pulmonary candidiasis. An important fact is that candidiasis is an
infection that can affect both immunocompromised and healthy people [37, 38].
Candidemia is the most relevant and prevalent nosocomial fungal infection associ-
ated with a high mortality rate (up to 49%) in patients with a compromised
immune system [39, 40]. The association of Candida with bloodstream infections
depends on patient’s condition, age, and geographic region. Candidemia is such an
important infection that in 10–40% of cases, it is associated with sepsis or septic
shock [41].
Candida albicans continues to be the most prevalent species isolated from fungal
infections [27, 42–44]. However, the prevalence of other Candida species has
increase substantially. These species are C. parapsilosis, C. tropicalis, C. krusei,
C. glabrata, C. guilliermondii, C. orthopsilosis, C. metapsilosis, C. famata, and
C. lusitaniae [44–46].
Candida species presents high degree of flexibility, being able to grow in
extremely different environments regarding to the availability of nutrients, tem-
perature variation, pH, osmolarity, and amount of available oxygen [47]. This fact
associated with the high resistance capacity of species to antifungals, their virulent
features, and capability of forming biofilms with other species [48, 49] makes the
genus Candida a serious risk to human health [50]. Thus, Candida species are highly
adaptable and possess numerous strategies to survive in conditions that can affect
their overgrowth and alter their susceptibility profiles.
Cryptococcus spp. may remain latent in the lungs, leading to asymptomatic
infection, or may cause multifocal lung disease. The latency period of Cryptococcus
can range from 6 weeks to more than 1 year after inhalation [51]. The fungus
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presents neurotrophism and can migrate to the central nervous system (CNS)
through hematogenous dissemination and, when crossing the blood-brain barrier,
can cause meningoencephalitis [13, 18]. Episodes of mental confusion in patients
with cryptococcosis have been described [52, 53]. Neurocryptococcosis is the most
severe form of the disease with high mortality rates in the absence of adequate
treatment [18, 23]. The mortality due to cryptococcosis is higher than the mortality
caused by tuberculosis and similar to that caused by malaria [54].
Another clinical manifestation is cutaneous cryptococcosis, which is rare and
usually secondary to hematogenous dissemination. Cutaneous lesions are charac-
terized by an infiltrative plaque of a solid tumor mass that can present ulcerative
and necrotic lesion [17]. Pulmonary and cutaneous lesions due to nodular features
may be misdiagnosed as tumor lesions [55]. In addition to the respiratory tract, CNS
and skin, other sites may be affected: prostate, eyes, adrenal glands, lymph nodes,
bone marrow, and liver [51].
Until now, there are three proposals to explain fungal neurotropism. The first is
that neuronal substrates present in the basal ganglia promote cryptococcal growth
and survival, and, thus, perivascular spaces may serve as a niche for Cryptococcus, as
described by [56] in a healthy female patient who had evidence of Cryptococcus
infection within the perivascular spaces of the parenchyma. The second proposal
describes that it is possible that there are specific neuronal receptors that can attract
Cryptococcus to the CNS [57]. The third hypothesis, one of the most widespread, is
that the fungus uses neurotransmitters such as dopamine that aids in the synthesis
of melanin [19, 57, 58].
Besides the clinical importance of fungal infections caused by theses pathogenic
yeasts, interestingly, climatic abnormalities due to phenomena such as La Niña and
El Niño have recently been described as important in the distribution and occur-
rence of mycoses in countries influenced by them [59].
3. Traditional antifungal agents against yeasts
In the last two decades, there has been an increasing, but limited, discovery of
antifungal agents [47]. These include azoles, such as fluconazole, itraconazole,
ketoconazole (KTC), miconazole, and clotrimazole, polyenes (amphotericin B
[AMB] and nystatin), allylamines, thiocarbamates, morpholines, 5-fluorocytosine,
and echinocandins (for instance, caspofungins) [21]. However, fungal cells and
human cells are eukaryotic, so antifungal compounds target both cell types,
resulting in considerable side effects in patients and fewer available targets for drug
action. Antifungals target three cellular components of fungi (Figure 1). Azoles
inhibit ergosterol biosynthesis by interfering with the enzyme lanosterol 14-α-
demethylase in endoplasmic reticulum of the fungal cell. This enzyme is involved in
the transformation of lanosterol into ergosterol, a component that is part of the
plasma membrane structure of the fungus (Figures 1 and 2). Thus, as the concen-
tration of ergosterol is reduced, the cell membrane structure is altered, thereby
inhibiting fungal growth [60].
Azoles comprise a five-member azole ring containing two (imidazole) or three
nitrogen atoms (triazole) attached to a complex side chain [61, 62]. Imidazoles
include KTC, miconazole, econazole, and clotrimazole, and triazoles include FLZ,
ITC, voriconazole (synthetic triazole derivative of FLZ of second generation), and
posaconazole (hydroxylated analog of itraconazole) [63].
AMB and nystatin bind to ergosterol causing the disruption of the membrane
structure and promoting extravasation of intracellular constituents such as ions and
sugars and, consequently, cell death [21] (Figure 1).
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Figure 1.
Mechanisms of action of some traditional antifungal agents on cellular targets. Azoles inhibit the ergosterol
synthesis in the endoplasmic reticulum of the fungal cell by interfering with the enzyme lanosterol 14-α-
demethylase. Polyenes act by binding to ergosterol present at the cell membrane. Echinocandins inhibit (1,3)
β-D-glucan synthase, thereby preventing glucan synthesis.
Figure 2.
Specific point of action of antifungal drugs in the ergosterol biosynthesis pathway.
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Pyrimidine analogs include 5-fluorocytosine and 5-fluorouracil (5FU). The first
has fungistatic properties and enters the fungal cell through cytosine permease,
inhibiting the thymidylate-synthetase enzyme and interfering with DNA. 5-fluoro-
uracil, which in turn can be phosphorylated to 5-fluorodeoxyuridine
monophosphate, can be incorporated into RNA molecules [63]. Due to toxicity
[64]; stronger side effects, such as hepatic impairment; interference with bone
marrow function; and rapid occurrence of resistance especially among Candida
species, the clinical use of 5-FC is preferred in association with AMB [65, 66].
In addition, the nephrotoxicity and hepatotoxicity of AMB and 5-FC, respectively,
and the unavailability of these antifungals in many countries have limited their use
in cryptococcal therapeutic [24].
Host’s immunity, type of infection, site of origin of the samples, toxicity, bio-
availability of the drug, and the sensitivity/resistance profile of the isolates interfere
in the choice of the type of agent to be used [22]. AMB is considered the gold
standard drug for most mycoses that affect patients at risk [67], although it has high
toxicity. Azoles have fungistatic properties that affect cell growth and proliferation
[65]. Among azoles, KTC was one of the firsts to emerge and was the first alterna-
tive to AMB [68]. Currently, FLZ is the drug of choice for most Candida and
Cryptococcus infections [64] and is the most recommended antifungal agent for use
in invasive candidiasis [47, 49].
For cryptococcosis, the choice of treatment depends on the patient’s immuno-
logical status and mainly on the clinical of the disease, if it is just a pulmonary
manifestation or if the infection is systemic. Fluconazole is recommended in cases
of lung disease with mild to moderate symptoms. Amphotericin B with or without
combination with 5-flucytosine is the recommended therapy for more serious
infections such as meningoencephalitis, followed by prolonged maintenance with
fluconazole [23, 24].
Although azoles are generally well-tolerated, they have limitations such as
hepatotoxicity and the emergence of resistance among fungal isolates [69] which
provide motivation for improving this class of antifungal agents [68]. For instance,
alterations in triazole molecule gave rise to voriconazole (structurally related to
FLZ) and posaconazole (related to ITC), both available for systemic therapy [66].
Echinocandins, which include caspofungin, micafungin, and anidulafungin, are a
new class of antifungals and have fungicidal effects in all Candida species [66]. They
inhibit (1,3) β-d-glucan synthase, thereby preventing glucan synthesis, which is
present in the cell membrane of fungi (Figure 1). As this drug acts on the wall
structure of the fungus, it has the advantage of a lower side effect in animal cells [47].
Allylamines (terbinafine and naftifine) and thiocarbamates inhibit the enzyme
squalene epoxidase, which participates in the synthesis of ergosterol and is encoded
by the ERG1 gene (Figure 2). This activity leads to membrane rupture and accu-
mulation of squalene. Allylamine effects can also prevent the production of other
sterol derivatives.
To minimize toxicity and resistance, some pharmacological strategies were
developed. The preparation and use of new antifungal formulas (liposomal AMB
(Ambisome®), AMB lipid complexes (Abelcet®), AMB colloidal dispersions
(Amphocil®/Amphotech®), and AMB lipid nanosphere formulations and
β-cyclodextrin itraconazole) are one strategy [68]. Others include combination
therapies of antifungal compounds (e.g., AMB + 5-FC, FLZ + 5-FC, AMB + FLZ,
caspofungin + liposomal AMB, and caspofungin + FLZ) and nanostructuring of
conventional antifungal agents [70–73].
However, all traditional antimycotic drugs have at least one restriction related to
their use. Some do not have a broad spectrum of action or are fungistatic. Others
have high toxicity and low bioavailability with significant side effects [74].
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Therefore, limitations of treatment and drug resistance associated with pathogenic-
ity of the clinical isolates support the urgent need to identify substances that are
more effective, with new mechanisms of action in the fight against Candida and
Cryptococcus infections.
4. Resistance in pathogenic yeasts: a significant problem
Most antifungals target sterols or the enzymes that synthesize them. However,
the fungistatic nature of many of these antifungals and emergence of clinical drug
resistance limits their success. Increased drug resistance in fungi is a problem that
cannot be avoided, particularly for FLZ, which is the preferred antifungal for
treating yeast infections [75].
The number of people at risk for fungal infections has been increasing, resulting
in an increased use of antifungal agents, even as prophylaxis. Thus, besides the
existence of some non-albicans Candida (NAC) species presenting inherent resis-
tance to azoles, higher minimum inhibitory concentrations (MICs) for antifungals
against C. albicans strains have been observed [76]. The World Health Organization
(2014) categorizes antimicrobial resistance as that developed by the microorganism
to an antimicrobial drug, which was initially effective in treatment of such infec-
tions. Low-dose prophylactic administration of azole derivatives, such as FLZ, for
prolonged periods to prevent the occurrence of opportunistic infections in
immunosuppressed patients also results in resistant phenotypes [27, 75]. Therapeu-
tic failures and empiric treatment are facts which are likely to collaborate to the
increased incidence of fungal infections.
In the last decade, a number of new clinical problems have arisen, requiring new
guidelines regarding the treatment of cryptococcosis, mainly because clinical data
have suggested that cryptococcal strains have become more resistant to drugs
[23, 25]. Some relates say that clinical Cryptococcus isolates are frequently less
susceptible to fluconazole than environmental isolates. However, Chowdhary et al.
[77] evaluated the susceptibility profile of environmental and clinical strains of
C. gattii and observed that environmental samples were less susceptible to flucona-
zole, itraconazole, and voriconazole in comparison to clinical isolates.
Heteroresistance is also a worrying phenomenon. It consists of the ability of a
subpopulation of microorganism to adapt to high concentrations of the drug,
resulting in resistant homogenous populations. However, heteroresistant strains
return to the initial phenotype when the stimulus with the drug is withdrawn [78].
Some mechanisms for cellular and molecular resistance to FLZ in yeasts are
described. In Candida and Cryptococcus, the first is related to the induction of
multidrug pumps, which decrease the concentration of drug available in the intra-
cellular compartment of yeast cells. Various genes belonging to the ATP-binding
cassette superfamily or to the major facilitator superfamily encode efflux pumps
were identified in C. albicans. Overexpression of some transporter genes or of their
regulated genes can confer cross-resistance to various azoles [21]. In C. gattii and
C. neoformans, AFR1,MDR1, and AFR2 genes encode ABC transporters that expel
the azole out of the fungal cell, thereby causing resistance to these drugs [79].
A second mechanism of resistance involves modification of the target enzyme
encoded by the ERG11 gene, also known as cytochrome P450 lanosterol 14-α-
demethylase (Cyp51). Mutations in this gene prevent azoles from binding to
enzyme sites. Another mechanism of resistance is related to mutations in the ERG3
gene which does not convert 14-α-methylfecosterol into 14-α-methyl-3,6-diol in the
ergosterol synthesis pathway. This substitution causes azoles to have no fungistatic
effects on the fungal cell membrane [21].
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Transcriptional regulation is also important for the development of resistance
mechanisms. YAP1, a protein, is important for the mechanism of C. neoformans
heteroresistance to fluconazole and oxidative stress. Mutant strains of C. neoformans
that lost protein YAP1 became hypersensitive to a variety of oxidizing agents and
mainly to fluconazole [80].
Resistance to polyenes (AMB) in fungus is less common and in C. albicans is
associated with the substitution of ergosterol with a precursor molecule or a general
reduction of sterols in the plasma membrane [81]. Reduction of membrane ergos-
terol renders Cryptococcus neoformans and Aspergillus spp. less susceptible to
amphotericin B [82]. Enzymes encoded by ERG3 and ERG2 genes participate in
ergosterol biosynthesis and have the main alterations related to AMB resistance
because mutations in their genes modify ergosterol content required for the action
of polyenes [83].
The main resistance mechanism to echinocandins is related with point mutations
in gene that encodes the major subunit of the glucan synthase enzyme (Fks subunit)
(Figure 1) and can provide resistance to all echinocandin [84]. Other Candida
species also present this resistance mechanism such as C. tropicalis, C. parapsilosis,
C. glabrata, C. krusei, C. guilliermondii, and C. dubliniensis [85, 86].
Resistance to 5-FC can be of two types: primary, occurring via cytosine permease
(encoded by the FCY2 gene) whose mutation decreases drug uptake [87], and
secondary, related to alterations in cytosine deaminase (encoded by FCY1) or uracil
phosphoribosyltransferase (encoded by FUR1) activities. Cytosine permease is
responsible by conversion of 5-FC to 5-fluorouridine or to 5-fluorouridine
monophosphate (5-FUMP) [88]. Resistance is easily developed in fungal isolates
from patients who are receiving the drug. However, other molecular mechanisms
related to resistance to 5-FC must exist because most of them have not been
observed in C. albicans [89].
The increase in the drug-resistant Candida and Cryptococcus strains to commer-
cial antifungals has caught the attention of clinicians and researchers to medicinal
plant products (commonly referred as phytochemicals). The use of phytochemicals
with greater antifungal potential and different mechanisms of action may be useful
in reducing the phenomenon of resistance. Lately, they have become a significant
alternative for discovery of commercially viable, economically cheaper, and safe
phytomedicines.
5. Medicinal plants as a source of antifungal agents
Global Action Fund for Fungal Infections (GAFFI), an international organiza-
tion working to reduce infections and deaths associated with fungi, has reported
that approximately 300 million people in the world suffer from a serious fungal
infection every year and that among them over 1.35 million deaths are
registered [90].
Despite the introduction of new and novel antifungal drugs, their production
and impact are slow, and the development of antifungal resistance has forced the
attention of researchers toward herbal products, mainly phytochemicals, in search
of development of safe and economically viable antifungals.
Populations around the world have used folk medicine as an alternative therapy
for various disorders. Currently, many species have been extensively studied in an
attempt to discover new biologically active compounds with novel structures and
mechanism of action for the development of new drugs.
Medicinal plants are commonly preferred because of their wide level of func-
tional chemical groups with comparatively poor toxic substances, low-cost extracts,
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fewer side effects, and easy accessibility to people. Various bioactive compounds
have been abundantly found such as phytochemicals.
Leaves, as well as the seeds and fruits of plants, have higher levels of phenolic
compounds. The concentration of these compounds also depends on the nature of
the chemical used as solvent in the extraction process as well as on the growth and
storage conditions [91].
The biological activity of plant products has been evaluated against fungi. The
ethanol extract, Lonicera japonica aerial parts, a medicinal plant of folk medicine
of China that used to treat some diseases, showed a very strong antimicrobial
activity against Candida species and potent wound healing capacity [92].
Methanolic extract of Lannea welwitschii leaves was antimicrobial against clinical
yeasts. A preliminary phytochemical screening of extracts revealed tannins,
flavonoids, alkaloids, and glycosides as compounds [93]. Pyrostegia venusta crude
flower extracts, fractions, and pure compounds showed an effective broad
spectrum antifungal activity [94].
An extract of Piper betle leaves inhibited the growth of Candida species [95], and
four different extracts of Strychnos spinosa showed anti-Candida activity [96].
Hydro-methanolic extracts of leaves from Juglans regia and Eucalyptus globulus and
methanol extract of Cynomorium coccineum demonstrated excellent antimycotic
property against Candida strains [91, 97]. Akroum [98] showed antifungal activity
in an acetylic extract of Vicia faba against C. albicans in vitro and reduced mortality
rates in Candida-infected mice that were treated with the extract.
Berberine, a protoberberine-type isoquinoline alkaloid isolated from the roots,
rhizomes, and stem bark of natural herbs, such as Berberis aquifolium, Berberis
vulgaris, Berberis aristata, Hydrastis canadensis, Phellodendron amurense, Coptis
chinensis, and Tinospora cordifolia, was described as powerful reducer of the viability
of in vitro biofilms formed by fluconazole-resistant Candida tropicalis cells [99].
Ethanolic and aqueous extracts from different plants from Brazilian Cerrado
commonly used in folk medicine such as Eugenia dysenterica and Pouteria ramiflora
were promising against C. tropicalis, C. famata, C. krusei, C. guilliermondii, and
C. parapsilosis. A phytochemical screening of active extracts from these plants
disclosed as main components flavonoids and catechins [100]. Crude extract and
fractions (n-butanolic and ethyl acetate ones) from Terminalia catappa leaves
showed antifungal properties against Candida spp.; hydrolysable tannins
(punicalin, punicalagin), gallic acid (GA), and flavonoid C-glycosides were the
active components found in butanolic fraction [101].
Bottari et al. [102] determined the antimicrobial activity of the aqueous and
ethanolic leaf extracts of Carya illinoensis. Both extracts had MIC values against
seven Candida reference strains between 25 and 6.25 mg/mL. Phenolic acids (gallic
acid and ellagic acid), flavonoids (rutin), and tannins (catechins and epicatechins)
were likely responsible, in part, for the activity against Candida strains. Further, the
extracts inhibited the production of C. albicans germ tubes.
5.1 Phytochemicals: polyphenols as substances most found in plants
Several woody plant produce medicinal phytochemicals such as polyphenols that
are low molecular weight naturally occurring organic compounds containing one or
more phenolic groups [103]. Further, polyphenols perform various substantial
functions in plant physiology and, therefore, can be found, in lesser or greater
quantity, in all of them.
Phenolic acids, flavonoids, tannins, and coumarins are some examples of phe-
nolic compounds found in and extracted from medicinal plants [104] (Table 1).
Research has shown that polyphenols have potentially healthy effects in
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humans, working primarily as anticancer, antihypertensive, anti-allergen,
anti-inflammatory, antioxidant, and antimicrobial agents. The antimicrobial activ-
ity of polyphenols has been extensively investigated mainly against bacteria [104].
Nevertheless, the antifungal activity of most of the phenolic compounds remains
unknown. There are few studies on the mechanism of action of the substance,
cytotoxicity, the synergism with traditional antifungals drugs, and their anti-
virulence activities.
Those with the most promising antifungal activity isolated from natural sources
include flavonoids, tannins, coumarins, quinones, lignans, and neolignans [105]
(Table 1).
Flavan-3-ols, flavonols, and tannins have received the most attention among
the known polyphenols, attributable to their large spectrum of efficacy and high
antimicrobial property. Structurally, flavonoids are aromatic compounds with 15
carbon atoms (C15) on their basic skeleton; they consist in tricyclic phenolic com-
pounds with two aromatic rings on their structure (C6–C3–C6) [105]. Flavonoids
are a class of natural compounds with several known protective activities, including
antifungal activity. The flavonoids include subclasses such as chalcones, flavones,
isoflavones, flavonols, flavanols (flavan-3-ol), and anthocyanidins [106].
The activity of flavonols such as quercetin, myricetin, and kaempferol has
been described in C. albicans. For instance, quercetin, myricetin, and kaempferol
from propolis have showed activity against Candida species [107]. The flavanol
subclass (flavan-3-ol) and gallotannin, extracted from Syzygium cordatum, also
Phytochemicals Bioactive compounds Properties Plant sources
Flavonoids Flavan-3-ol Against Candida Syzygium cordatum
Baicalein, gallotannin Against Candida Scutellaria baicalensis
Coumarins Ulopterol AgainstM. canis Skimmia laureola
Prenyletin; prenyletin-
methyl-ether
Against T. rubrum;
T mentagrophytes
—
Osthenol C. albicans, Fusarium solani,
A. fumigatus
—
5,8-
Dihydroxyumbelliprenin
T. interdigitale,M. gypseum Ferula foetida
Saponins Colchiside Phytopathogenic fungi Dipsacus asper roots
Terpenes or
terpenoids
Triterpenes Against dermatophytes Ethyl acetate leaf
extract of Satureja
khuzestanica
Lectins Lectins Fusarium oxysporum Seed from native
Amazon species
Tannins Punicalagin
Punicalin
Against Candida spp. Terminalia catappa
Punicalagin T. mentagrophytes; T. rubrum;
M. canis;M. gypseum
Punica granatum
Ellagic acid, gallagic acid,
punicalins, punicalagin
C. albicans, Cryptococcus
neoformans, Aspergillus
fumigatus
Punica granatum
Lambertianin C, sanguiin
H-6
Geotrichum candidum Rubus idaeus
Table 1.
Phytochemicals with antifungal compounds derived from plants.
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showed inhibitory properties on the growth of C. albicans [108]. Serpa et al. [109]
isolated baicalein, belonging to a subclass of flavones, from Scutellaria baicalensis,
and induced apoptosis in C. albicans (Table 1), and apigenin, a flavone isolated
from propolis, showed antifungal potential. Flavonoids as much as coumarins
and lignans have shown an antifungal potential against several species of
dermatophytes [105].
Other important groups of polyphenolic compounds present in various plant
parts, such as the roots, flowers, leaves, fruits, and seeds, are tannins. They are
divided into hydrolyzable (ellagitannins) and condensed tannins (proantho-
cyanidins) and gallotannins [110]. They have the ability to precipitate macromole-
cules such as proteins [111] as well as have antimicrobial properties. However, the
mechanisms underlying the antimicrobial action of tannins in different microor-
ganisms are still under investigation [111].
Ellagitannins constitute a complex class of polyphenols characterized by one or
more hexahydroxydiphenoyl (HHDP) which can be linked in various ways to the
glucose molecule [112]. Ellagic acid, gallagic acid, punicalins, and punicalagins
isolated from ethyl acetate and butanolic fractions of Punica granatum revealed
antifungal activity against C. albicans, Cryptococcus neoformans, and Aspergillus
fumigatus [113] (Table 1).
Ellagitannins isolated from Ocotea odorifera, a plant commonly used in Brazil in
folk medicine, have a potential against C. parapsilosis [114]. Two ellagitannins
isolated from raspberry (Rubus idaeus L.) fruit, lambertianin C and sanguiin H-6,
showed fungistatic activity both in vitro and in situ against Geotrichum candidum
[115]. Dos Santos et al. [111] verified that encapsulated tannins from Acacia mearnsii
have moderate activity against Aspergillus niger (ATCC 9642) and C. albicans
(ATCC 34147).
Coumarins have a C6-C3 skeleton, possessing an oxygen heterocycle as part of
the C3 unit [105]. These compounds are known to play a role in disease and pest
resistance, as well as UV tolerance. The antifungal activity of 40 coumarins was
tested against reference strains of Candida albicans, Aspergillus fumigatus, and
Fusarium solani, but among them only osthenol showed the most effective antifun-
gal activity (Table 1). The authors argue that the action of osthenol can be related to
the presence of an alkyl group at C-8 position [116].
Another coumarin derivative, 4-acetetatecoumarin, was effective in inhibiting
Aspergillus spp., acting on the factors of virulence and affecting the structure of the
fungal wall. Diversinin, a coumarin isolated from the petroleum ether extract of
Baccharis darwinii, demonstrated antifungal activity against T. rubrum,
T. mentagrophytes, andM. gypseum, being fungicidal. Another coumarin derivative,
5,8-dihydroxyumbelliprenin, isolated from Ferula foetida, was active against
M. gypseum and Trichophyton interdigitale [105] (Table 1).
Phenylpropanoids are other naturally occurring compounds categorized as
coumarins, phenylpropanoic acid, and lignans frequently studied for their anti-
Candida properties [117]. Navarro-Garcia et al. [118] and Raut et al. [119] found
that a coumarin (scopoletin) and two phenylpropanoic acids (salicylaldehyde and
anisyl alcohol) have antifungal property against C. albicans, with MICs of 25, 31,
and 31 μg/mL, respectively.
Shahzad et al. [103] observed the effectiveness of pyrogallol and curcumin
(CUR) against various C. albicans clinical isolates. In addition, curcumin inhibited
the adhesion capability of cells and demonstrated anti-biofilm activity. Curcumin is
a flavonoid found in turmeric (Curcuma longa L.). Pure curcumin had potential
activity against Cryptococcus gattii both in vitro and in vivo [120]. According to
Ferreira et al. [121], the essential oil from Curcuma longa L. can reduce the colony
diameter, germination, and sporulation of Aspergillus flavus.
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Alalwan et al. [122] undertook a series of adsorption experiments with varying
concentrations of curcumin and showed that 50 μg/mL could prevent adhesion of C.
albicans SC5314 to denture materials. Curcumin-silver nanoparticles also showed
potential anticandidal activity against fluconazole-resistant Candida species isolated
from HIV patients with MIC range of 31.2–250 μg/mL [123].
Gallic acid is a polyphenol natural compound found in many medicinal plant
species that has been shown to have anti-inflammatory and antibacterial properties.
GA was found to have a broad spectrum of antifungal activity against dermatophyte
and Candida strains. Authors verified that GA reduced the activity of sterol 14-α-
demethylase P450 (CYP51) and squalene epoxidase in the T. rubrum membrane.
Teodoro et al. [124] demonstrated that acetone fraction from Buchenavia
tomentosa aqueous extract and its major compound gallic acid had the ability to
inhibit reference strains C. albicans ATCC 18804 and Candida albicans SC 5314
adherence and to disrupt 48 h-biofilm.
5.2 Essential oils as potential antifungal
In the eagerness to research and develop new substances to suppress the devel-
opment of pathogenic fungi from natural plant substances, knowledge about the
biological activities of essential oils has been growing. Essential oils’ pharmacologi-
cal activities, mainly related to their complex chemical composition and high con-
centrations of phenols, make these compounds particularly interesting for both the
treatment and the prevention of fungal infections. Natural phenolic substances are
among the most antifungal active substances present in essential oils, generally
showing low toxic effects in animals [125]. They consist in a complex mixture of
monoterpene and sesquiterpene hydrocarbons and oxygenated derivatives such as
alcohols, aldehydes, ketones, and phenylpropanoids.
Essential oils are also called volatile oils or ethereal oils, as they have a high
degree of evaporation when exposed to air. The presence of terpenes contributes to
the complex constitution with the action against microorganisms being directly
related to this characteristic [126]. Since ancient times, Mondello et al. [127]
proposed that tea tree oil could be used in antifungal therapy, because it showed
efficacy against multidrug-resistant Candida species in vitro and against mucosal
candidiasis in vivo; they have also showed that terpinen-4-ol was the main
substance presented in the oil which contribute to the anticandidal activity.
Several oils have demonstrated activity against Candida species. Sharifzadeh
et al. [128] observed that essential oils from Trachyspermum ammi have anticandidal
effects against isolates resistant to FLZ. Herbal essences from Foeniculum vulgare,
Satureja hortensis, C. cyminum, and Zataria multiflora were tested against
C. albicans. Essential oils from Z. multiflora showed the best anticandidal
activity [129].
Carica papaya essential oils have inhibitory effects against Candida species,
detected by agar diffusion and microdilution assays [130]. Minooeianhaghighi et al.
[131] verified that a combination of essential oils from Cuminum cyminum and
Lavandula binaludensis showed growth inhibition of C. albicans isolates, at very low
concentrations (between 3.90 and 11.71 μg/mL). Essential oils from Cymbopogon
nardus have also shown antimicrobial potential against Candida species, with
inhibition of hyphal growth in C. albicans at concentrations between 15.8 and
1000 μg/mL. This oil also inhibited growth of filamentous fungus from the envi-
ronment. Main compounds of C. nardus essential oil were the oxygen-containing
monoterpenes: citronellal, geranial, geraniol, citronellol, and neral [126]. In addition
to inhibiting biofilm formation [132], essential oils from Artemisia judaica have been
shown to inhibit the formation of germination tubes in C. albicans and have shown
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that at a very low concentration (0.16 μL/mL), it inhibited 80% of Candida
filamentation. Kose et al. [133] demonstrated the fungicidal potential of essential
oils from Centaurea baseri against Candida species, with an MIC of 60 μg/mL.
Among the monoterpenes there is thymol (2-isopropyl-5-methylphenol) [134].
It is the most abundant constituent in essential oils from Thymus vulgaris (thyme)
[135] and the major component of essential oils from Origanum vulgare (oregano)
[136]. Thymol showed antifungal activity, fungistatic and fungicidal one, against
Candida strains. Authors verified an MIC of 39 μg/mL against C. albicans and
C. krusei and MIC of 78 μg/mL against C. tropicalis. Probably thymol acts by binding
to ergosterol in the plasma membrane, thereby increasing ion permeability and
resulting in cell death because an eightfold increase (from 39.0 to 312.5 μg/mL) in
thymol MIC values against C. albicans was seen in the presence of exogenous
ergosterol. A combination of thymol and nystatin resulted in synergy [137].
Terpenoids have shown synergistic effects with FLZ, so it may be useful as a
candidate antifungal chemotherapeutic agent. In addition, terpenoids exhibit a very
good antimycotic activity of filamentous-form growth of C. albicans at nontoxic
concentrations [138]. Further, in experiments realized by [139], rubiarbonol G, a
triterpenoid from Rubia yunnanensis, showed potent antimicrobial activity against
C. albicans, with an MIC of 10.5 μg/mL.
The antifungal potential of terpenes, geraniol, and citronellol has been investi-
gated previously, with effective inhibitory activity against C. albicans [138] and
filamentous fungi of the Aspergillus species [140]. In addition, Mesa-Arango et al.
[67] showed that oxygenated monoterpenes in the citral chemotype, such as gera-
niol, citral, and citronellal, have antifungal activity against C. parapsilosis, C. krusei,
Aspergillus flavus, and Aspergillus fumigatus.
Terpenes’ anti-biofilm activity and the efficacy of thymol, geraniol, and carvacrol
in the treatment of Candida infections associated with the use of hospital devices
have been related [141]. Effects of carvacrol on Candida cells can be associated with
alterations in the cytoplasmic membrane and induction of apoptosis [108].
Although the process of discovering bioactive molecules is complex and time-
consuming, involving isolation, identification, and optimization of pharmacokinetic
and pharmacodynamic properties, as well as the selection of lead compounds for
further drug development, data related here showed that plants are a promising
source of active molecules with antifungal properties. Biological assays have shown
that plant extracts or essential oils and their bioactivity molecules inhibit ATCC and
clinical strains of fungi species, including those with resistance to drugs employed
in medical practice. In addition, some are able to inhibit and control the main
virulence factors of fungi species, such as the formation and proliferation of hyphae
and filamentation and, more importantly, the eradication of mature biofilms.
Eugenol (4-allyl-2-methoxyphenol) is a phenolic compound and the main con-
stituent of the essential oil isolated from the Eugenia caryophyllata. There are reports
of some pharmacological effects of eugenol, such as antifungal and antibacterial
agent, and its anti-Candida action seems to be related to the generation of oxidative
stress concomitantly with lipid peroxidation of the cell membrane of Candida
albicans yeast and the generation of reactive oxygen species [142]. Eugenol also
showed antifungal effects against both Cryptococcus gattii and C. neoformans cells by
causing morphological alterations, changes of cellular superficial charges, and oxi-
dative stress. Thymol and carvacrol can represent alternative, efficient, and cost
effective drugs for anti-biofilm therapy for Cryptococcus species.
Eugenol showed activity against Alternaria spp. and P. chrysogenum, by agar
diffusion method [143] and, along with other monoterpenes such as carvacrol and
isoeugenol, exhibited strong antifungal activity against Rhizopus stolonifer and
Absidia coerulea [144].
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5.3 Synergistic action between phytochemicals and antifungals
Resistance mechanisms are developed by fungi to the treatment with conven-
tional drugs in addition to toxic side effects to human cells showed by these drugs;
researchers’ efforts in developing new strategies to improve treatment effectiveness
of fungal infection are growing, with an interest in plants and folklore medicine.
The knowledge about synergistic effects of plant extracts or their compounds
with traditional agents is nowadays a type of study that has aroused interest. Some
in vitro screening assays have evidenced that plant extracts are less toxic than
existing antifungal agents and, in combination with them, could reduce toxicity and
increase antifungal potential [21, 145].
Accordingly, combination antifungal therapy offers the possibility of broaden-
ing the spectrum of drug activity, reducing toxicity, and decreasing fungal
resistance [146].
Although combination of medications requires a careful evaluation of the
synergistic, antagonistic, and agonist properties of the drugs involved [147], the use
of drug combinations in treatment of infections by fungi is a common preferred
strategy clinically. In many cases of fungal infection, combination therapy has been
used successfully [21]. For some examples, see Table 2.
There are two main hypotheses about the type of interaction resulting from the
combination of fluconazole and amphotericin B, based on the mechanisms of action
of these drugs. In the theory of depletion, the interaction between fluconazole and
amphotericin B would result in antagonism due to pre-exposure to fluconazole,
which would lead to depletion of the membrane ergosterol, and thus there would be
a decrease in the available sites for amphotericin B. In the second theory, the
synergism, amphotericin B would lead to the formation of pores, which would
facilitate the greater access of azole to the intracellular space, which by inhibiting
the enzymes involved in ergosterol biosynthesis would increase the antimicrobial
Combination of antifungals Target References
AMP B + posaconazole
AMP B + caspofungin
AMP B + fluconazole
Candida biofilms
Candida biofilms
Cryptococcosis in murine model
[148]
[54]
[149]
Micafungin + fluconazole
Micafungin + voriconazole
Micafungin + AMP B
Micafungin + isavuconazole
Candida infections [150]
[151]
[152]
Flucytosine + voriconazole Candida infections [148]
Minocycline + fluconazole Candida albicans biofilms [148]
Posaconazole + caspofungin Candida infections [153]
[154]
Terbinafine + azole Candida growth [155]
[156]
Echinocandin + azole Invasive candidiasis [157]
AMP B + flucytosine Invasive candidiasis [158]
Natamycin + 5-fluorouracil Fusarium species ocular isolates [159]
AMP B: amphotericin B.
Table 2.
Various regimes of combinatorial antifungal therapy showing better efficacy in combination than that of
independent drugs (adapted from [21]).
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efficacy. According to these theories, the combination of fluconazole and
amphotericin B could involve different interactions [160–162].
Considering the difficulties regarding to the treatment of candidiasis and cryp-
tococcosis, the combination of antifungals represents an important alternative to
conventional therapy. The synergistic effects of drugs are primarily attributable to
cell wall damage by one antifungal. Thus, this component potentiates the activity of
other drugs exactly against some constituent of plasma membrane. Alternatively,
compromised cell wall with an increased permeability could facilitate movement
of drugs across the cell membrane to their targets. Or, the synergistic action of
different drugs occurs because they act on different targets of the same pathway,
which can happen, for example, with the combination of azoles and allylamines.
The objective of this strategy is to maximize the antifungal effects. Tangarife-
Castaño et al. [163] reported synergy between essential oils or plant extracts associ-
ated with antifungal drugs when used as anti-C. albicans agents. The best synergistic
effects were obtained from the combination between itraconazole and P.
bredemeyeri extract against C. albicans.
Synergistic potential was observed when methanolic extract of T. catappa leaves
was combined with nystatin or AMB against reference strains of C. albicans, Can-
dida neoformans, C. glabrata, Candida apicola, and Trichosporon beigelii [164]. The
combination showed maximum synergy against C. apicola.
Santos et al. [165] related synergistic antifungal activity of an ethanol extract of
Hyptis martiusii in combination with metronidazole against C. albicans, C. krusei,
and C. tropicalis. Avijgan et al. [166] reported a potent synergistic effect between
an Echinophora platyloba ethanolic extract and itraconazole or FLZ against isolates
of C. albicans from vaginal secretions of patients with recurrent vulvovaginitis,
significantly lowering the concentrations of both substances.
A combination between thymol and nystatin was found to have synergistic
effects against Candida species [137], reducing the MICs of both products by 87.4%.
Synergism was observed between a water insoluble fraction from U. tomentosa bark
and terbinafine, as well as between it and FLZ against seven resistant isolates of
C. glabrata and C. krusei [167]. Synergistic effects led to cell damage, and authors
demonstrated, through differential scanning calorimetry and infrared analysis, that
intermolecular interactions between the extract components and either terbinafine
or FLZ occurring outside the cell wall are likely responsible for synergistic effects
observed between substances.
Subfraction combinations of Terminalia catappa,Terminalia mantaly, and
Monodora tenuifolia showed synergistic interactions against C. albicans, C. glabrata,
C. parapsilosis, and C. neoformans isolates. Synergistic combination between
M. tenuifolia and T. mantaly subfractions also showed fungicidal effects against
most tested strains [168].
The combination therapy with curcumin and fluconazole was the most effective
among the treatments tested against Cryptococcus gattii. The association was able to
reduce the fungal burden and damage on lung tissues of infected mice and to
eliminate the fungal burden in the brain, enhancing the survival of mice with
C. gattii-induced cryptococcosis [120].
Methanolic extract of Buchenavia tetraphylla is a great source of antimicrobial
compounds and enhanced the action of FLZ against different C. albicans isolates
from vaginal secretions as well as azole-resistant isolates. The extract increased the
action of FLZ in most strains through additive (20% of strains) or synergistic (60%
of strains) effects [169].
Kumari et al. [170] investigated the effect of six essential oil compounds sourced
from oregano oil (carvacrol), cinnamon oil (cinnamaldehyde), lemongrass oil
(citral), clove oil (eugenol), peppermint oil (menthol), and thyme oil (thymol)
15
Phytochemicals and Their Antifungal Potential against Pathogenic Yeasts
DOI: http://dx.doi.org/10.5772/intechopen.87302
against three infectious forms: planktonic cells, biofilm formation, and preformed
biofilm of C. neoformans and C. laurentii. The anti-biofilm activity of the tested
compounds was in the order thymol > carvacrol > citral > eugenol = cinnamaldehyde
> menthol. The three most potent compounds thymol, carvacrol, and citral showed
best anti-biofilm activity at a much lower concentration against C. laurentii. In the
presence of these potent compounds, assays revealed the absence of extracellular
polymeric matrix, reduction in cellular density, and alteration in the surface mor-
phology of biofilm cells. In addition they were the most efficient in terms of human
safety in keratinocyte-Cryptococcus spp. co-culture infection model suggesting that
thymol, carvacrol, and citral can be further exploited as cost-effective and nontoxic
anti-cryptococcal drugs.
The lectin pCramoll from Cratylia mollis, a native forage plant endemic to the
semiarid region of Brazil (caatinga biome), showed an immunomodulatory effect
and a synergism in combination with fluconazole, increasing the survival of animals
with cryptococcosis caused by C. gattii and improving aspects of morbidity present
in the progression of cryptococcosis [171].
Thymol exhibited synergistic effects when combined with fluconazole against
clinical species of Candida, enhancing the antifungal potential of the drug and
decreasing the concentration required for the effect [172]. Zaidi et al. [173] found
that methanolic extract of leaves of Ocimum sanctum in combination with flucona-
zole showed higher antifungal potential and synergistic activity against resistant
Candida spp. than methanolic extract or fluconazole when used alone.
Essential oils were also recently proposed to increase drug effectiveness.
Lavandula and Rosmarinus essential oils were selected as antiproliferative agents to
compound lipid nanoparticles for clotrimazole delivery in treatment of Candida
skin infections. Authors confirmed the potential anti-Candida activity of the
selected oils due to their interaction with membrane permeabilization. In addition,
in vitro studies against Candida albicans, Candida krusei, and Candida parapsilosis
showed an increase of the antifungal activity of clotrimazole-loaded nanoparticles
prepared with Lavandula or Rosmarinus, thus confirming that nanostructured lipid
carriers (NLC) containing these essential oils represent a promising strategy to
improve drug effectiveness against topical candidiasis [174].
A novel therapeutic strategy that has been adopted is photodynamic therapy
(PDT). It is based on the interaction between a nontoxic photosensitizer and a safe
source of visible light at a low intensity; the combination of these two factors in the
presence of oxygen leads to the development of reactive oxygen species (ROS)
which are toxic and cause oxidative damage to microorganism cells [175]. Curcumin
associated with LED light was an efficient strategy against biofilms of C. dubliniensis
isolates [176]. The uptake of CUR by yeast cells and its penetration through the
biofilm were accompanied by confocal laser scanning microscopy. Daliri et al. [177]
have assessed the effect of curcumin- and methyl blue-mediated PDT in combina-
tion with different laser exposure parameters on C. albicans colonies. They verified
that the 460-nm laser in combination with CUR has the maximum antifungal
efficiency against C. albicans.
Although we have described herein many in vitro studies examining synergistic
effects among potential antifungal biomolecules and traditional antifungal agents,
the mechanisms underlying these synergistic effects are poorly understood.
Randomized and controlled analyses have been performed with the objective
of verifying the efficacy and risks of using traditional antifungal combinations;
however, the results are poor and contradictory. High cost to conduct these
strategies, reduced number of clinical cases, and the existence of confusing
variables are factors that contribute to the obtaining of vague and non-reproducible
results.
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Therefore, it is extremely relevant to examine carefully possible synergism
between new phytocompounds and conventional antimycotic drugs in order to
obtain more insight. Understanding the cellular action of each substance in the
combination process is also a key step in inferring ways to employ strategy in the
clinic. A lack of consensus in the medical clinic emphasizes the need to conduct
further clinical trials using combinations of antifungals. The experiments and
results addressed herein support further investigation of new plant constituents
with antifungal properties and the efficacy of combination therapies involving
phytocomponents and traditional antifungal agents as an important start for the
development of unusual and original antifungal therapies.
6. Conclusions
The increase in Candida and Cryptococcus infections is alarming leading to high
rates of morbidity and mortality worldwide. Concomitantly with the increase in
fungal infections, species emerged, and the resistance phenomenon increased so
that the available antifungal arsenal becomes irrelevant in the face of the problem.
In addition, there are limitations manifested by some antifungal agents such as
fungistatic character, severe toxicity, and renal dysfunction. Therefore, it is crucial
to develop new drugs as alternative therapies that are potentially active against
Cryptococcus and Candida. Plants are considered abundant and safe sources of
phytochemicals endowed with many biological activities. Several polyphenols have
been isolated and studied in relation to their anti-yeast and anti-virulence activities
and may be useful in obtaining promising, efficient, and cost-effective drugs for the
inhibition of Candida and Cryptococcus infections. Many phytosubstances are
extremely effective in combination therapy with traditional or other phytochemi-
cals, which can be further exploited to lead to novel drug therapies against recalci-
trant infections.
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